Dear Editor, Waterman et al. recently showed that a modified regimen of pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma (MM) [1] . We really appreciated these data that were similar to results that we already described in similar patients [2] . We treated a total of 25 patients (11 females and 14 males) with a median age of 61 years at diagnosis (range, 40-69) who were resistant/relapsed after at least one prior therapy. The scheme therapy was based on VMD: bortezomib, 1.3 mg/m 2 as intravenous bolus twice a week for 2 weeks (on days 1, 4, 8, and 11 of each cycle) in a 28-day cycle for a total of 4 cycles; oral dexamethasone (24 mg) on the day of each bortezomib dose and the day after, and PLD (Myocet®) (30 mg/m 2 ) on day 4 of each cycle, 1 h after bortezomib infusion. Baseline characteristics are shown in Table 1 . All 25 patients were evaluable for response. Response rates following VMD showed 2 patients in near complete response (nCR) (10%), 4 in very good partial response (VGPR) (20%), 14 in partial response (PR) (70%), resulting in an overall response rate of 80%. Global toxicities were lower and included neutropenia (12.5%), fatigue (25%), thrombocytopenia (25%), and neuropathy (37.5%).
We also treated 14 different patients with a combination regimen of lenalidomide (25 mg d 1-21), PLD, and dexamethasone (RMD); 11 patients between 44 and 76 (median age 65) were eligible for evaluation. All the patients had MM with Durie-Salmon stage II or III and were resistant or have progressed progression after 1-5 previous anti-myeloma regimens. RMD was administered for six 28-day cycle. PLD (Myocet®) 30 mg/m 2 d4, Dex 40 mg d1-4 and 17-20. Eight of 11 patients (73%) achieved an objective response to therapy.
Respectively, two patients (25%) have VGPR and additional six patients (75%) have PR. The most common side effect was hematological toxicity with grade 3/4 neutropenia (48%), thrombocytopenia (38%), and anemia (16.6%). Under thrombosis prophylaxis with aspirin 100 mg per day, we observed thromboembolic complications in only one patient (4.5%). Other non-haematological side effects were pain (grade 3/4, one patient), infection (grade 3/4, one patient), diarrhea (grade 3/4, two patients). Neither neurotoxicity nor constitutional symptoms of grade 3/4 was found.
In our study, lenalidomide or bortezomib in combination with PLD and dexamethasone has shown encouraging activity in heavily pretreated patients with relapsed or refractory MM. These schemes can be an additional standard of care in the treatment of patients with relapsed or refractory MM who have received at least one prior therapy [3] . The addition of PLD can play a key role in overcoming anthracycline resistance and improving the quality of response without limiting toxicity. The pharma-cology of PLD gives rise to a compound with major advantages that could potentially improve response and decrease toxicity. Because increased angiogenic activity occurs in the bone marrow of patients with MM, this pegylated formulation can enhance the delivery of doxorubicin to the tumor site. In addition, because myeloma cells divide slowly, the increased exposure of these cells to doxorubicin has the potential of overcoming resistance and increasing tumor cell killing capacity, theoretically resulting in improved response rates [4] .
